SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies is trending due to a surge in stock price following news of a U.S. patent allowance for their lung cancer detection technology; the community is actively discussing dip buys, halt alerts, and potential price targets. Some traders believe the stock is undervalued, while others caution about potential dilution and resistance levels, impacting the overall sentiment around BIAF.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending due to positive phase 3 trial results for its oral Wegovy pill, showing comparable weight loss to the injectable version, which could broaden its market appeal. Community discussions revolve around the drug's potential to revolutionize obesity treatment and the company's competitive positioning against Eli Lilly. Some investors believe Novo Nordisk is undervalued, while others discuss potential tariff impacts and production capabilities in the US.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

KODK is trending as investors discuss its potential in pharmaceutical manufacturing and the possible impact of government initiatives. Community members are speculating on the timing of news related to pension settlements and potential government contracts, while also weighing the company's value relative to its assets. Some traders are pointing to technical indicators and short interest, suggesting a possible short squeeze scenario.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending as traders react to its Q4 earnings report, with mixed sentiment despite the company beating expectations. Community discussions revolve around the impact of tariffs, membership fees, and overall valuation, especially compared to tech stocks. Some analysts have downgraded the stock, while others maintain a positive outlook, adding to the debate.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

CRNX is trending due to JMP Securities raising its price target significantly, sparking community discussion about a potential short squeeze given the high short interest and institutional ownership. Some traders are taking profits after the FDA approval news, while others believe the stock has more room to run based on analyst upgrades and potential for further catalysts. The community is actively debating price targets and entry/exit strategies.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending amidst speculation regarding its potential involvement in a TikTok deal, although many community members are tempering expectations. Discussions also revolve around the pending Northern Data acquisition and the anticipated launch of the Rumble Wallet, with some expressing frustration over delays.  The stock's high short interest and ties to figures close to a certain political figure are also fueling conversations.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to a J.P. Morgan downgrade, which the community believes is an attempt to manipulate the stock price for cheap acquisition, while others view the dip as a buying opportunity given the company's focus on AI cloud infrastructure. Community members are actively discussing the company's potential for growth in the AI sector, especially as compared to other companies such as Palantir, and anticipating a deal announcement to further drive momentum.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending amid reports of potential large aircraft orders from Turkey and Uzbekistan, with community members anticipating a significant deal announcement. Discussions revolve around the potential impact of increased aircraft orders on production capacity and stock performance, with some suggesting the stock is oversold. Boeing's defense partnership with Palantir to integrate AI is also generating buzz.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cannabis Stock CRLBF Gains 25% in a Month: Time to Buy, Sell or Hold?

CRLBF surges 25% this month on reform hopes, but revenue declines, margin pressure and stiff competition cloud its outlook.

Cresco Labs Inc. (CRLBF) Reports Q2 Loss, Lags Revenue Estimates

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -25.00% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Lags Q2 Earnings and Revenue Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -3.39% and -2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +7.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cannabis Operator CRLBF Plans California Exit: How to Play the Stock?

Cresco plans to exit California, citing tough market dynamics, as it sharpens focus on high-margin growth markets.

Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?

GTBIF slides 30% YTD as rising costs, flat revenues and tight U.S. rules weigh on margins and investor sentiment.

Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?

CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.

Cresco Labs Inc. (CRLBF) on Friday reported a decline in its first-quarter revenue while losses widened, sending shares down 8% in midday trading.The company, which makes branded cannabis products, <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250529949504/en/Cresco-Labs-Continues-Track-Record-of-Delivering-Strong-Operating-Cash-Flow">reported</a> revenue of $166 million for the three months through the end of March, down from the $184 million reported in the corresponding period of 2024.However, this surpassed an analyst estimate of $165 million, as per Finchat data.The Sunnyside dispensaries operator reported a net loss of $15 million for the quarter, compared to a loss of $2 million in the corresponding period of last year.Adjusted earnings before interest, taxes, depreciation, and amortization came in at $36 million, in line with an analyst estimate of $35.9 million, but below the $54 million reported in the first quarter (Q1) of 2024.The company ended the quarter with cash, cash equivalents, and restricted cash of $159 million, as well as senior secured term loan debt, net of discount and issuance costs, of $353 million. The company also had a mortgage loan, net of discount and issuance costs of $18 million.Cresco was initially slated to report earnings earlier this month, but postponed it to provide additional time to complete procedures for reviewing its first-quarter financial statements.On Stocktwits, retail sentiment around CRLBF rose from ‘neutral’ to ‘bullish’ territory while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_1_49_08_PM_png_4ee23c9749.webp" alt="CRLBF's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 30, 2025 | Source: Stocktwits" width="631" height="57"><figcaption>CRLBF's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed skepticism about the OTC counter, calling it ‘a cautionary tale.’<stembedurl>https://stocktwits.com/BobStillSizzlin/message/616337292</stembedurl>According to data from Koyfin, six of seven analysts covering the Cresco stock rate it ‘Buy’ or higher, while one rates it a ‘Hold’.<a href="https://stocktwits.com/symbol/CRLBF">CRLBF</a> is down by 34% this year and by about 66% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-jamie-dimon-enemy-within-china-potential-adversary/ch0uPM9RbuQ">Jamie Dimon Warns Of The Enemy Within, Says He’s Not As Worried About China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Cresco Labs is displayed on the screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cresco Labs’ Q1 Loss Widens, Revenue Declines: Retail Terms It A ‘Cautionary Tale’ For Investors

The Sunnyside dispensaries operator reported a net loss of $15 million for the quarter, compared to a loss of $2 million in the corresponding period of last year.

Equity

The Sunnyside dispensaries operator reported a net loss of $15 million for the quarter, compared to a loss of $2 million in the corresponding period of last year.


Trump Is Pushing to Supercharge the Marijuana Industry. 2 ‘Strong Buy’ Stocks to Buy

Wall Street sees triple-digit upside in AAWH and CRLBF as regulatory momentum builds.

Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.

CRLBF
Cresco Labs Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRLBF News

CRLBF Cresco Labs Inc